(AOF) – Boiron laboratories achieved activity of 147.52 million euros in the fourth quarter of 2021, up 2.9% over one year. Thus, over the full year, sales amounted to 455.2 million euros, down 11.4%, following the delisting of homeopathy on January 1, 2021 in France. , and the absence of winter pathologies in the first quarter, attributable to the context of the global health crisis. Full year operating profit is expected to rise thanks to growth in Q4. As a reminder, in 2020, this amounted to 38.2 million euros.
Boiron explains that the drop in activity in 2021 has been contained thanks to sales of new products which amount to around 50 million euros, a significant part of which comes from sales of COVID tests, mainly in France and Belgium.
In addition, the group also announced the signing of an agreement to acquire a majority stake of 70% in the company ABBI, a start-up specializing in individualized and made-to-measure cosmetics. This acquisition will be effective no later than February 28, 2022 subject to the fulfillment of conditions precedent.
The amount of the acquisition of this stake is 1.75 million euros, to which may be added an additional price depending on the performance of the ABBI company.
On June 30, 2025, Laboratoires Boiron will acquire the remaining 30% for an amount that will also depend on the performance of ABBI. These amounts will be financed from the Group’s own funds.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.